Immix Biopharma, Inc. — Form 8-K Summary
Report date: September 29, 2026. This 8-K reports clinical-trial developments; it does not provide quarterly or annual financial results.
Business context and clinical update
Immix announced results from its fully enrolled, 45-patient U.S. Phase 2 NEXICART-2 trial of NXC-201, a sterically optimized CAR-T candidate, in relapsed/refractory light chain (AL) amyloidosis. The trial has a registrational design.
- An independent review committee assessed a complete response (CR) rate of 89% (40 of 45 patients) across all enrolled patients.
- All 25 newly enrolled patients are either in CR or minimum residual disease (MRD)-negative.
- The company reported that all patients who achieved MRD-negativity to date reached CR within one year of treatment. Four pending patients are already MRD-negative; the company said this could potentially increase the CR rate to 98% (44 of 45).
- No relapses have been observed to date among patients who reached CR or MRD-negativity.
- No neurotoxicity or enterocolitis has been observed to date. Safety data through August 4, 2026 was described as generally consistent with previously reported NEXICART-2 safety data.
Financial metrics and comparison
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It also does not provide a comparable prior-period financial or clinical-results table.
Outlook, risks, and contingencies
The company plans a final NEXICART-2 readout and a biologics license application (BLA) submission in mid-2027. These are forward-looking plans, not guarantees. The potential 98% CR rate is also conditional on future outcomes. The company cautions that clinical-trial timing and results, regulatory developments, and other risks could cause actual results to differ; it refers investors to risk factors in its 2025 Form 10-K and subsequent SEC filings.
Key facts for investors to verify
- Review the underlying trial data, including patient follow-up, response definitions, and the status of the four MRD-negative pending patients.
- Confirm the duration and completeness of relapse and safety monitoring; “to date” findings do not establish long-term outcomes.
- Track whether the planned mid-2027 final readout and BLA submission remain on schedule and whether the FDA’s requirements or regulatory pathway change.
- Consult the company’s periodic SEC filings for financial condition, cash runway, and other financial information not included in this 8-K.
The clinical announcement was furnished under Item 7.01 and is not deemed “filed” for purposes of Exchange Act Section 18, as described in the filing.